AQR Capital Management LLC Boosts Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

AQR Capital Management LLC raised its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 25.7% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 7,587 shares of the company’s stock after acquiring an additional 1,551 shares during the period. AQR Capital Management LLC’s holdings in Krystal Biotech were worth $1,393,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Scout Investments Inc. purchased a new stake in shares of Krystal Biotech in the 1st quarter valued at about $8,976,000. Sei Investments Co. boosted its holdings in shares of Krystal Biotech by 128.3% in the first quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock valued at $6,005,000 after acquiring an additional 18,968 shares during the period. Vanguard Group Inc. increased its holdings in shares of Krystal Biotech by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after acquiring an additional 35,632 shares during the period. Janney Montgomery Scott LLC purchased a new stake in Krystal Biotech in the 1st quarter valued at $3,175,000. Finally, Price T Rowe Associates Inc. MD raised its position in Krystal Biotech by 54.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after purchasing an additional 231,255 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

KRYS has been the subject of several recent research reports. Citigroup reiterated a “neutral” rating and set a $204.00 target price (up previously from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. HC Wainwright boosted their target price on Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Evercore ISI boosted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. Finally, Chardan Capital raised their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $196.75.

Krystal Biotech Trading Up 0.7 %

Shares of KRYS opened at $173.15 on Friday. The firm’s 50-day moving average is $187.55 and its two-hundred day moving average is $179.97. Krystal Biotech, Inc. has a twelve month low of $93.95 and a twelve month high of $219.34. The firm has a market capitalization of $4.94 billion, a P/E ratio of 92.59 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The firm had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. Krystal Biotech’s quarterly revenue was up 70283900.0% on a year-over-year basis. During the same period last year, the business posted ($1.25) EPS. Analysts predict that Krystal Biotech, Inc. will post 3.13 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).